Company / Free Cash Flow
United Therapeutics Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$1.0B
FY2025
5-year range
$477.4M / $1.1B
FY2021-FY2025
Trend
-3.7%
vs FY2024
Sector context
#15 of 194
Health Care
What the data says
Among 194 Health Care companies, United Therapeutics is in the top 8% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from -$290M in FY2019 to $1.1B in FY2024.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of +8.4%. Top quartile in the Health Care sector.
Improved from $748M to $1.0B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +16.2%
- 5-Year CAGR
- +8.4%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 194This company $1.0B Sector average $470.6M
▼
+121.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +8.4%, indicating consistent growth.
- In FY2025, free cash flow decreased 3.7% year-over-year.
- Ranks #15 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | -3.7% |
| FY2024 | $1.1B | +44.5% |
| FY2023 | $747.6M | +12.6% |
| FY2022 | $663.7M | +39.0% |
| FY2021 | $477.4M | -31.4% |
| FY2020 | $696.4M | +339.9% |
| FY2019 | -$290.3M | -148.9% |
| FY2018 | $594.0M | +78.4% |
| FY2017 | $333.0M | -45.0% |
| FY2016 | $605.6M | +81.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026